New PCs for a new Windows

Touch, tap, and swipe

The latest PCs are designed for touch, so whether you're playing a game, surfing the web, or scrolling through a PowerPoint, you can interact with Windows 8.1 in fun and exciting new ways.

Powerful and portable

The new generation of Windows 8.1 tablets, laptops, and two-in-ones are thin, light, long-lasting, and powerful, so you can take your PC with you wherever you go and stay powered up and connected all day long.

More ways to work and play

Catch up on email, prepare a presentation, make a Skype call. Surf the web, download a new game, watch a favorite movie. Windows 8.1 PCs bring you an endless array of options for productivity and entertainment.

New PCs for a new Windows

Designed to bring out the best in Windows 8.1, the latest PCs come in a range of striking styles, from sleek, portable, and versatile tablets to space-saving all-in-one desktop PCs sporting big, beautiful displays.

Now's the time for a new PC

Windows 8.1 was designed to power an exciting and affordable new generation of PCs. Find the one that's right for you.

Explore PCs

A tablet, a laptop, and an all-in-one running Windows 8.1

Comments

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition. In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates. So, why is this approval so important? First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com . Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday. It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly? The answer isn't clear yet. We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct. But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side

DBTECH

Search This Blog